BLACKROCK SMALLER COMPANIES TRUST plc
All information is at 31 May 2008 and unaudited.
Performance at month end is calculated on a capital only basis
One Three One Three Five
Month Months Year Years Years
Net asset value 6.0% 8.0% -9.6% 67.6% 162.9%
Share price 9.4% 8.1% -11.6% 76.0% 187.7%
HGSC ex Inv Trust + AIM* 1.1% -1.5% -21.5% 14.3% 55.8%
Sources: BlackRock and Datastream
*With effect from 1 September 2007 the Hoare Govett Smaller Companies plus AIM
(ex Investment Companies) Index replaced the FTSE SmallCap Index (ex Investment
Companies) as the Company's benchmark. For the one year, three year and five
year periods above the index has been blended to reflect this.
At month end
Net asset value (debt at par value): 440.49p
Net asset value (debt at fair value): 437.19p
Net asset value incl. Income (debt at par value) 442.95p*
Net asset value incl. Income (debt at fair value) 439.65p*
Share price: 367.50p
Discount to Capital only NAV (debt at par value): 16.6%
Discount to Capital only NAV (debt at fair value): 15.9%
Net yield: 1.3%
Total assets: £230.0m^
Gearing: 6.4%
Ordinary shares in issue^: 48,509,708
(* includes net revenue of 2.46p)
(^ includes current year revenue)
Ten Largest Sector
Weightings % of Total Assets
Support Services 14.0
Software & Computer Services 11.9
Industrial Metals & Mining 9.6
Oil & Gas Producers 9.0
Industrial Engineering 8.7
Financial Services 7.9
Aerospace & Defence 6.3
Electronic & Electrical Equipment 4.6
Media 3.7
Health Care Equipment & Services 3.6
Total 79.3
Ten Largest Equity Investments (in alphabetical order)
Company
Albidon
Aveva Group
Chloride Group
Connaught
Dechra Pharmaceuticals
Hill & Smith Holdings
ITE Group
Rathbone Brothers
Spirax-Sarco Engineering
Victrex
Commenting on the markets, Mike Prentis, representing the Investment Manager
noted:
During May the Company's NAV rose by 6.0%. The benchmark index rose by 1.1%,
whilst the FTSE100 index fell by 0.5%.
In relative terms, the best stock contributions came from Dechra
Pharmaceuticals, Chloride Group, ITE Group, Albidon, Aveva Group and Nighthawk
Energy. Dechra shares are very defensive, given that health-related spending on
dogs, cats and other pets is generally regarded as non-discretionary. FDA
approval for Vetoryl should come through this year. Chloride shares were firm
on hopes of a competitive bid situation developing. In early June bid talks
were terminated; underlying trading remains strong. ITE produced strong year
end results; a significant part of its revenues are Euro denominated, and this
is leading to earnings upgrades. Albidon continues to move towards production
from its Munali nickel mine. Aveva again produced strong results; management
remain very confident about prospects. Nighthawk announced further positive
drilling success.
The worst performer during the month was Detica, although this cost us only 13
basis points in relative terms. In fact Detica has just produced good full year
results and management remain confident; the shares gave up some ground after a
good run.
New holdings included our first investment in an IPO for some time, OPG Power
Ventures. OPG owns power stations in India and was raising money to build
several new plants. We added to our holding in Hampson Industries helping to
fund a major acquisition.
We sold several of our holdings in oil & gas producers, including holdings in
Dana Petroleum, JKX Oil & Gas and Oilexco. These have all performed well in
recent months. We also sold our long standing holding in Chaucer Holdings,
taking a view that Lloyd's underwriters may remain dull for some time.
Latest information is available by typing www.blackrock.co.uk/its on the
internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV
terminal).
26 June 2008
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.